



Public Health Division
122 West 25th Street, 3rd Floor West
Cheyenne, WY 82002
(307) 777-6004 • 800-599-9754
Fax (307) 777-8687 • www.health.wyo.gov



Stefan Johansson
Interim Director

Mark Gordon
Governor

State Health Advisory

COVID-19 Monoclonal Antibody Update

Coronavirus Disease 2019 Advisory #13.1

Wyoming Department of Health (WDH)

September 14, 2021

COVID-19 MONOCLONAL ANTIBODY ORDERING AND DISTRIBUTION

On September 14, 2021, The U.S. Department of Health and Human Services (HHS) notified the Wyoming Department of Health (WDH) that providers will no longer be able to order COVID-19 monoclonal antibodies directly from AmerisourceBergen. Beginning September 14, 2021, HHS will determine each state's weekly amount of monoclonal antibody products based on COVID-19 case burden and monoclonal antibody utilization. WDH will then allocate to providers within Wyoming. HHS has made this change due to a substantial increase in the utilization of monoclonal antibody drugs necessitating this measure to ensure consistent and continuing availability across the country.

WDH will distribute this week's allocations based on outstanding orders that Wyoming providers have already submitted to HHS for doses of bamlanivimab plus etesevimab. Doses of casirivimab and imdevimab (REGEN-COV) will need to be distributed on a pro rata basis as the current orders placed exceed Wyoming's allocation. HHS has allocated 50 doses of bamlanivimab plus etesevimab and 360 doses of casirivimab and imdevimab (REGEN-COV) to Wyoming for the current week. WDH will subsequently distribute based on the number of active cases by county, or through a method as recommended by the WDH Medical Ethics Committee.

This change in monoclonal antibody distribution may mean that monoclonal antibody therapies will not be available to all patients who qualify. WDH will consult with the WDH Medical Ethics Committee to determine recommendations for prioritizing patients to receive these therapies. In the meantime, providers should use clinical judgement and consider prioritizing treatment over post-exposure prophylaxis when necessary.

BAMLANIVIMAB AND ETESEVIMAB

Due to data indicating that bamlanivimab plus etesevimab is effective against the delta variant, which is currently the dominant variant in the United States, the pause on the use of bamlanivimab and etesevimab has been lifted by HHS. Bamlanivimab plus etesevimab in

combination may currently be used in Wyoming and distribution of this monoclonal antibody combination through allocation by WDH has begun. Providers that have non-expired doses of bamlanivimab plus etesevimab may initiate their use immediately.

SOTROVIMAB

WDH has not received any information that the availability of Sotrovimab has been affected by this change in distribution of the other monoclonal antibodies. Sotrovimab may be purchased through the distributor AmerisourceBergen. Details about how to purchase sotrovimab can be found here: <https://www.sotrovimab.com/hcp/access/>

OTHER THERAPIES AND CLINICAL MANAGEMENT GUIDANCE

Clinical management guidance is available from the CDC (<https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html>), the NIH (<https://www.covid19treatmentguidelines.nih.gov/>), and the IDSA (<https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/>). CDC's Clinical Outreach and Communication Activity (COCA) calls and webinars offer the most up to date information and guidance for clinicians. COCA calls can be accessed at <https://emergency.cdc.gov/coca/calls/index.asp>. The Wyoming Medical Society website contains clinical resources from the University of Washington, including treatment guidelines and algorithms: <https://www.wyomed.org/resources/covid-19/>.

CONTACT INFORMATION

Wyoming healthcare providers and facilities are reminded to check COVID-19 resources available from WDH <https://health.wyo.gov/publichealth/infectious-disease-epidemiology-unit/disease/novel-coronavirus/> and CDC <https://www.cdc.gov/coronavirus/2019-nCoV/>. Healthcare providers or facilities can contact WDH through the following channels:

- Please email questions about preparedness, PPE, infection control, or other non-urgent topics to wdh.covid19@wyo.gov. This email address is monitored 7 days a week and replies will come within 24 hours.
- Please contact WPHL with questions about specimen collection, storage, or shipping at 307-777-7431 or WPHL@wyo.gov.
- **Please use the WDH Public Health Emergency Line (1-888-996-9104) for urgent questions. This line is intended ONLY for healthcare providers. Do not share this number with the public.**

Please refer questions from the general public to 211 or to the WDH email box (wdh.covid19@wyo.gov).